INXN 2001

Drug Profile

INXN 2001

Alternative Names: Ad-IL-12; Ad-RTS-hIL-12; Ad-RTS-hIL-12 + veledimex; Ad-RTS-IL-12; Ad-RTS-mIL-12; ZIN-ATI-001

Latest Information Update: 06 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator ZIOPHARM Oncology
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action Gene transference; Interleukin-12 expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Breast cancer
  • Phase I Glioma
  • Suspended Malignant melanoma
  • Discontinued Colorectal cancer

Most Recent Events

  • 06 Jun 2017 Adverse event data from a phase I trial in Glioma presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 05 Jun 2017 Efficacy, pharmacodynamics and drug interactions data from a phase I trial in Glioma presented at the Annual Meeting of American Society of Clinical Oncology (ASCO-2017)
  • 01 May 2017 INXN 2001 is available for licensing as of 01 May 2017. www.ziopharm.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top